Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated July 1, 2020, reports the appointment of Torsten Hombeck, Ph.D., as Chief Financial Officer, effective June 30, 2020. The filing details the terms of his Executive Employment Agreement and his professional background.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and employment terms.
- Base Salary: $290,000 annually.
- Target Bonus: 30% of base salary.
- Initial Stock Option Grant: 7,000,000 Ordinary Shares (70,000 ADSs).
- Future Stock Option Grant: 3,000,000 Ordinary Shares (30,000 ADSs) contingent on employment as of January 1, 2021.
Material Changes
The primary material change is the addition of Dr. Hombeck to the executive team. He had previously served as a financial consultant to the Company since October 2019. No financial performance changes or operational shifts are reported in this document.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. It outlines specific contractual risks and contingencies related to the CFO's employment:
- Termination Provisions: Severe termination payments apply if the Company terminates without cause or if Dr. Hombeck resigns for "good reason." Payments range from 50% to 100% of 12 months' base salary plus the target bonus, depending on the timing relative to July 1, 2021.
- Change of Control: In the event of a change of control within one year of termination, severance sums are multiplied by 1.5 times, and medical insurance coverage extends to 18 months.
- Stock Vesting: Options vest ratably over four years but accelerate upon a change of control.
Investor Verification Checklist
- Verify the dilution impact of the 10,000,000 Ordinary Shares (100,000 ADSs) in total stock options granted to the new CFO.
- Review the full Executive Employment Agreement (Exhibit 10.1) to understand the specific definitions of "good reason" and "cause."
- Assess the potential cash outflow for severance in a "without cause" termination scenario, which could exceed $200,000 in immediate cash plus bonus and benefits.
- Confirm the exercise price of the stock options, which is set at the closing price on the grant date.